See more : B.Grimm Power Public Company Limited (BGRIM.BK) Income Statement Analysis – Financial Results
Complete financial analysis of RegeneRx Biopharmaceuticals, Inc. (RGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RegeneRx Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Eevia Health Plc (EEVIA.ST) Income Statement Analysis – Financial Results
- Benefitfocus, Inc. (BNFT) Income Statement Analysis – Financial Results
- ALM Equity AB (publ) (ALM-PREF.ST) Income Statement Analysis – Financial Results
- Takachiho Koheki Co.,Ltd. (2676.T) Income Statement Analysis – Financial Results
- Rakuten Group, Inc. (RKUNF) Income Statement Analysis – Financial Results
RegeneRx Biopharmaceuticals, Inc. (RGRX)
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.76K | 76.76K | 76.76K | 76.76K | 69.67K | 56.65K | 93.31K | 60.61K | 0.00 | 29.48K | 1.34M | 1.51M | 849.54K | 0.00 | 168.41K | 240.32K | 272.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27K | 215.03K | 542.24K | 105.59K |
| Cost of Revenue | 0.00 | 6.64 | 4.92 | 65.11 | 81.04 | 3.05K | 237.34 | 203.19 | 367.28 | 188.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.76K | 76.75K | 76.76K | 76.70K | 69.59K | 53.60K | 93.07K | 60.41K | -367.28 | 29.30K | 1.34M | 1.51M | 849.54K | 0.00 | 168.41K | 240.32K | 272.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27K | 215.03K | 542.24K | 105.59K |
| Gross Profit Ratio | 100.00% | 99.99% | 99.99% | 99.92% | 99.88% | 94.62% | 99.75% | 99.66% | 0.00% | 99.36% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 6.64K | 4.92K | 65.11K | 81.04K | 143.91K | 237.34K | 203.19K | 367.28K | 188.64K | 1.16M | 5.07M | 2.71M | 3.72M | 7.11M | 8.89M | 6.40M | 4.03M | 2.18M | 775.75K | 885.63K | 139.12K | 64.80K | 1.28K | 41.34K | 85.70K | 1.05M | 2.75M |
| General & Administrative | 1.42M | 1.40M | 1.37M | 1.27M | 1.31M | 1.36M | 1.53M | 1.57M | 1.19M | 755.09K | 1.02M | 2.46M | 3.17M | 2.78M | 3.85M | 3.20M | 2.67M | 1.64M | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 59.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.48M | 1.40M | 1.37M | 1.27M | 1.31M | 1.36M | 1.53M | 1.57M | 1.19M | 755.09K | 1.02M | 2.46M | 3.17M | 2.78M | 3.85M | 3.20M | 2.67M | 1.64M | 1.16M | 848.74K | 559.64K | 356.58K | 398.64K | 200.89K | 551.75K | 784.32K | 968.57K | 2.06M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -582.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.48M | 1.41M | 1.37M | 1.34M | 1.39M | 1.50M | 1.77M | 1.77M | 1.56M | 943.74K | 2.18M | 7.52M | 5.88M | 6.51M | 10.96M | 12.08M | 9.06M | 5.67M | 3.34M | 1.62M | 1.45M | 495.70K | 463.43K | 202.17K | 593.09K | 870.01K | 2.02M | 4.81M |
| Cost & Expenses | 1.48M | 1.41M | 1.37M | 1.34M | 1.39M | 1.50M | 1.77M | 1.77M | 1.56M | 943.74K | 2.18M | 7.52M | 5.88M | 6.51M | 10.96M | 12.08M | 9.06M | 5.67M | 3.34M | 1.62M | 1.45M | 495.70K | 463.43K | 202.17K | 593.09K | 870.01K | 2.02M | 4.81M |
| Interest Income | 183.00 | 234.00 | 3.81K | 11.04K | 0.00 | 0.00 | 0.00 | 101.00 | 153.00 | 16.00 | 26.00 | 4.49K | 8.19K | 12.44K | 149.78K | 666.46K | 522.70K | 214.68K | 16.44K | 7.57K | 30.08K | 30.03K | 18.70K | 0.00 | 4.88K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 325.65K | 324.88K | 232.63K | 153.41K | 87.28K | 170.88K | 173.36K | 172.88K | 183.47K | 100.94K | 5.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00 | 42.95K | 0.00 | 0.00 | 0.00 | 0.00 | 14.52K | 0.00 | 132.07K | 0.00 |
| Depreciation & Amortization | 183.00 | 1.33M | 1.42K | 27.22K | 2.75K | 3.05K | 3.33K | 3.40K | 4.82K | 5.00K | 7.57K | 9.08K | 9.74K | 16.55K | 19.40K | 21.20K | 18.11K | 15.63K | 4.18K | 4.10K | 3.29K | 1.23K | 731.00 | 305.00 | 1.30K | 5.04K | 77.19K | 306.63K |
| EBITDA | -1.40M | -1.27M | -1.29M | -1.25M | -1.90M | -1.44M | -1.67M | -5.09M | -1.55M | -565.40K | -833.73K | -6.00M | -5.02M | -6.48M | -10.79M | -11.16M | -8.25M | -5.44M | -3.32M | -1.62M | -1.45M | -691.25K | -1.17M | 291.30K | -588.52K | -649.94K | -1.40M | -4.40M |
| EBITDA Ratio | -1,826.20% | -1,730.41% | -1,681.50% | -1,627.65% | -2,732.31% | -2,544.63% | -1,790.51% | -2,814.68% | 0.00% | -3,083.83% | -62.09% | -397.10% | -591.19% | 0.00% | -6,393.46% | -4,919.78% | -3,219.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -70,192.86% | -302.67% | -253.80% | -4,308.75% |
| Operating Income | -1.40M | -1.33M | -1.29M | -1.26M | -1.32M | -1.44M | -1.67M | -1.71M | -1.56M | -914.25K | -841.33K | -6.01M | -5.03M | -6.51M | -10.79M | -11.84M | -8.79M | -5.67M | -3.34M | -1.62M | -1.45M | -495.70K | -463.43K | -202.17K | -589.83K | -654.98K | -1.48M | -4.71M |
| Operating Income Ratio | -1,826.44% | -1,730.71% | -1,686.46% | -1,643.89% | -1,899.56% | -2,550.01% | -1,794.08% | -2,820.46% | 0.00% | -3,100.84% | -62.65% | -397.70% | -592.33% | 0.00% | -6,404.97% | -4,928.60% | -3,225.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,065.08% | -304.59% | -272.70% | -4,457.81% |
| Total Other Income/Expenses | -325.46K | -269.24K | -228.83K | -142.37K | -670.18K | 1.83M | 1.90M | -3.56M | -1.20M | 242.91K | -5.67K | 4.49K | 8.19K | 12.44K | 149.78K | 11.84M | 522.71K | 214.68K | 16.37K | 0.00 | 10.65K | 196.78K | 704.39K | -493.16K | 589.83K | 911.00 | -25.28K | 149.25K |
| Income Before Tax | -1.73M | -1.60M | -1.52M | -1.40M | -1.99M | 385.09K | 229.13K | -5.27M | -2.75M | -671.34K | -847.00K | 0.00 | 0.00 | 0.00 | -11.18M | -11.18B | 0.00 | 0.00 | 0.00 | 0.00 | -1.43M | -298.92K | 240.96K | -695.33K | 1.11M | -654.07K | -1.50M | -4.56M |
| Income Before Tax Ratio | -2,250.43% | -2,081.47% | -1,984.56% | -1,829.35% | -2,861.55% | 679.75% | 245.56% | -8,695.44% | 0.00% | -2,276.97% | -63.08% | 0.00% | 0.00% | 0.00% | -6,637.39% | -4,651,286.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 34,102.63% | -304.17% | -277.36% | -4,316.47% |
| Income Tax Expense | 0.00 | 324.64K | 228.83K | 153.41K | -582.90K | 98.61K | 173.36K | 172.88K | 183.47K | 100.94K | 26.00 | -4.49K | -8.19K | -12.44K | -541.19K | 665.79M | -522.70K | -214.68K | -16.37K | 35.38K | -40.73K | -345.09K | -1.50M | 509.07K | -2.35M | 140.45K | 157.35K | -614.85K |
| Net Income | -1.73M | -1.92M | -1.75M | -1.56M | -1.99M | 286.49K | 229.13K | -5.27M | -2.75M | -671.34K | -847.00K | -6.01M | -5.02M | -6.49M | -10.64M | -11.18M | -8.27M | -5.45M | -3.33M | -1.66M | -1.40M | -150.61K | 1.04M | -711.23K | 1.76M | -795.43K | -1.64M | -4.09M |
| Net Income Ratio | -2,250.43% | -2,504.40% | -2,282.66% | -2,029.20% | -2,861.55% | 505.70% | 245.56% | -8,695.44% | 0.00% | -2,276.97% | -63.08% | -397.40% | -591.37% | 0.00% | -6,316.04% | -4,651.29% | -3,033.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 53,953.08% | -369.91% | -301.71% | -3,875.52% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.05 | -0.03 | -0.01 | -0.01 | -0.08 | -0.07 | -0.12 | -0.21 | -0.24 | -0.21 | -0.15 | -0.10 | -0.06 | -0.06 | -0.01 | 0.06 | -0.06 | 0.15 | -0.07 | -0.18 | -0.46 |
| EPS Diluted | -1.20 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.05 | -0.03 | -0.01 | -0.01 | -0.08 | -0.07 | -0.12 | -0.21 | -0.24 | -0.21 | -0.15 | -0.10 | -0.06 | -0.06 | -0.01 | 0.05 | -0.06 | 0.15 | -0.07 | -0.18 | -0.46 |
| Weighted Avg Shares Out | 143.55M | 138.59M | 133.36M | 130.97M | 120.72M | 107.44M | 106.79M | 101.53M | 93.19M | 81.73M | 81.63M | 80.14M | 68.44M | 55.68M | 50.97M | 46.47M | 40.12M | 36.84M | 32.91M | 28.52M | 25.56M | 19.48M | 18.85M | 11.98M | 11.74M | 11.36M | 9.09M | 8.98M |
| Weighted Avg Shares Out (Dil) | 1.44M | 138.59M | 133.36M | 130.97M | 120.72M | 120.93M | 125.92M | 101.53M | 93.19M | 81.73M | 81.63M | 80.14M | 68.44M | 55.68M | 50.97M | 46.47M | 40.12M | 36.84M | 32.91M | 28.52M | 25.56M | 19.48M | 20.83M | 11.98M | 11.74M | 11.36M | 9.09M | 8.98M |
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database...
RegeneRx Comments on ARISE-3 Clinical Trial
ROCKVILLE, Md., Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3...
Source: https://incomestatements.info
Category: Stock Reports